Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Radiotherapy for breast cancer often involves some incidental exposure of the heart to ionizing radiation. The effect of this exposure on the subsequent risk of ischemic heart disease is uncertain. METHODS: We conducted a population-based case-control study of major coronary events (i.e., myocardial infarction, coronary revascularization, or death from ischemic heart disease) in 2168 women who underwent radiotherapy for breast cancer between 1958 and 2001 in Sweden and Denmark; the study included 963 women with major coronary events and 1205 controls. Individual patient information was obtained from hospital records. For each woman, the mean radiation doses to the whole heart and to the left anterior descending coronary artery were estimated from her radiotherapy chart. RESULTS: The overall average of the mean doses to the whole heart was 4.9 Gy (range, 0.03 to 27.72). Rates of major coronary events increased linearly with the mean dose to the heart by 7.4% per gray (95% confidence interval, 2.9 to 14.5; P<0.001), with no apparent threshold. The increase started within the first 5 years after radiotherapy and continued into the third decade after radiotherapy. The proportional increase in the rate of major coronary events per gray was similar in women with and women without cardiac risk factors at the time of radiotherapy. CONCLUSIONS: Exposure of the heart to ionizing radiation during radiotherapy for breast cancer increases the subsequent rate of ischemic heart disease. The increase is proportional to the mean dose to the heart, begins within a few years after exposure, and continues for at least 20 years. Women with preexisting cardiac risk factors have greater absolute increases in risk from radiotherapy than other women. (Funded by Cancer Research UK and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent evidence shows risk at lower doses (<0.5 Gy), with an estimated latency of 10 years or more29–31.”
From Red risks for a journey to the red planet: The highest priority human health risks for a mission to Mars (2020) · cites this paper as [29]
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Applied Regression Analysis and Other Multivariable Methods
Walker, E. (1989) · Technometrics · doi:10.1080/00401706.1989.10488486 · Cited by 8,538
(2011) · The Lancet · doi:10.1016/s0140-6736(11)61629-2 · Cited by 3,937
Self-citationCardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
The completeness of the Swedish Cancer Register – a sample survey for year 1998
Barlow, L., Westergren, K., Holmberg, L., & Talbäck, M. (2009) · Acta Oncologica · doi:10.1080/02841860802247664 · Cited by 1,236
Radiation Dose–Volume Effects in the Heart
Gagliardi, G., Constine, L. S., Moiseenko, V., Correa, C., Pierce, L. J., Allen, A. M., & Marks, L. B. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.04.093 · Cited by 1,227
Self-citationDarby, S. C., McGale, P., Taylor, C. W., & Peto, R. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70251-5 · Cited by 1,049
Self-citationLifetime risks of cardiovascular disease
Berry, J. D., Dyer, A., Cai, X., Garside, D. B., Ning, H., Thomas, A., Greenland, P., Van Horn, L., Tracy, R. P., & Lloyd-Jones, D. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1012848 · Cited by 945
Cuzick, J., Stewart, H., Rutqvist, L., Houghton, J., Edwards, R., Redmond, C., Peto, R., Baum, M., Fisher, B., & Host, H. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.3.447 · Cited by 889
Self-citation
Research works printed but not linked: 1
- Jones B, 2001, Clin Oncol (R Coll Radiol), 13, 71
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Cancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Self-citationZamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
“The most exposed coronaries are the left anterior descending during left breast irradiation and the left main stem, circumflex and right coronary arteries during treatment for Hodgkin lymphoma.(132,133) A higher prevalence of stress test abnormalities has been found among women irradiated for left breast cancer compar…”
BackgroundSelf-citationZamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
“The most exposed coronaries are the left anterior descending during left breast irradiation and the left main stem, circumflex and right coronary arteries during treatment for Hodgkin lymphoma.(132,133) A higher prevalence of stress test abnormalities has been found among women irradiated for left breast cancer compar…”
BackgroundLoibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Haviland, J. S., Owen, J. R., Dewar, J. A., Agrawal, R. K., Barrett, J., Barrett-Lee, P. J., Dobbs, H. J., Hopwood, P., Lawton, P. A., Magee, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70386-3 · Cited by 1,470
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,334
Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., Dent, S., Douglas, P. S., Durand, J.-B., Ewer, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5400 · Cited by 1,290
Murray Brunt, A., Haviland, J. S., Wheatley, D. A., Sydenham, M. A., Alhasso, A., Bloomfield, D. J., Chan, C., Churn, M., Cleator, S., Coles, C. E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30932-6 · Cited by 1,084
Cardiovascular Disease in Women: Clinical Perspectives
Garcia, M., Mulvagh, S. L., Bairey Merz, C. N., Buring, J. E., & Manson, J. E. (2016) · Circulation Research · doi:10.1161/circresaha.116.307547 · Cited by 1,080
“dose to the heart, beginning within a few years after exposure, and continuing for at least 20 years.(85) Women with preexist-”
Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., Cannady, R. S., Pratt-Chapman, M. L., Edge, S. B., Jacobs, L. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3809 · Cited by 1,071
Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.023 · Cited by 1,031
“Many anticancer therapies are known to have deleterious effects on the cardiovascular (CV) system.(4,5) The anticancer therapies with associated CV complications or toxicities are summarised in supplementary Table S1, available at Annals of Oncology online.”
BackgroundInternal Mammary and Medial Supraclavicular Irradiation in Breast Cancer
Poortmans, P. M., Collette, S., Kirkove, C., Van Limbergen, E., Budach, V., Struikmans, H., Collette, L., Fourquet, A., Maingon, P., Valli, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415369 · Cited by 1,005
A population-based study of cardiovascular disease mortality risk in US cancer patients
Sturgeon, K. M., Deng, L., Bluethmann, S. M., Zhou, S., Trifiletti, D. M., Jiang, C., Kelly, S. P., & Zaorsky, N. G. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz766 · Cited by 923
De Ruysscher, D., Niedermann, G., Burnet, N. G., Siva, S., Lee, A. W. M., & Hegi-Johnson, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0064-5 · Cited by 868
Kunkler, I. H., Williams, L. J., Jack, W. J. L., Cameron, D. A., & Dixon, J. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71221-5 · Cited by 904
Mehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz-Flores, S., Dent, S., Kondapalli, L., Ky, B., Okwuosa, T., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000556 · Cited by 848
Lyon, A. R., Dent, S., Stanway, S., Earl, H., Brezden-Masley, C., Cohen-Solal, A., Tocchetti, C. G., Moslehi, J. J., Groarke, J. D., Bergler-Klein, J., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1920 · Cited by 815
Sex differences in heart failure
Lam, C. S. P., Arnott, C., Beale, A. L., Chandramouli, C., Hilfiker-Kleiner, D., Kaye, D. M., Ky, B., Santema, B. T., Sliwa, K., & Voors, A. A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz835 · Cited by 802
Vaidya, J. S., Wenz, F., Bulsara, M., Tobias, J. S., Joseph, D. J., Keshtgar, M., Flyger, H. L., Massarut, S., Alvarado, M., Saunders, C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61950-9 · Cited by 831
Eyck, B. M., van Lanschot, J. J. B., Hulshof, M. C. C. M., van der Wilk, B. J., Shapiro, J., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03614 · Cited by 795
“Patients receiving radiotherapy to the chest are also at risk of late cardiopulmonary toxicity.(14,15) Within the CROSS trial, adverse events were not recorded after the initial 2-year report of the trial, potentially leading to underestimation of the toxicity of the CROSS regimen.”
BackgroundTaylor, C., Correa, C., Duane, F. K., Aznar, M. C., Anderson, S. J., Bergh, J., Dodwell, D., Ewertz, M., Gray, R., Jagsi, R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.0722 · Cited by 785
Self-citationCardiotoxicity of anticancer treatments: Epidemiology, detection, and management
Curigliano, G., Cardinale, D., Dent, S., Criscitiello, C., Aseyev, O., Lenihan, D., & Cipolla, C. M. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21341 · Cited by 723
Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens‐Alvarado, R. L., Cannady, R. S., Pratt‐Chapman, M. L., Edge, S. B., Jacobs, L. A., et al. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21319 · Cited by 728
“monal/endocrine therapy with aromatase inhibitors have been associated with an increased risk of cardiovascular disease in patients with breast cancer.(70,71) The risk of heart disease increases in postmenopausal women, as endogenous estrogens in younger women contribute to the low preva-”
Strnad, V., Ott, O. J., Hildebrandt, G., Kauer-Dorner, D., Knauerhase, H., Major, T., Lyczek, J., Guinot, J. L., Dunst, J., Miguelez, C. G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00471-7 · Cited by 659
The expanding role of primary care in cancer control
Rubin, G., Berendsen, A., Crawford, S. M., Dommett, R., Earle, C., Emery, J., Fahey, T., Grassi, L., Grunfeld, E., Gupta, S., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00205-3 · Cited by 555
“Examples include the development of osteoporosis after endocrine therapies, 149 heart disease after certain types of chemotherapy or radiotherapy, 150 and the development of second cancers.”
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 542
Pathological effects of ionizing radiation: endothelial activation and dysfunction
Baselet, B., Sonveaux, P., Baatout, S., & Aerts, A. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2956-z · Cited by 552
Inflammaging and Oxidative Stress in Human Diseases: From Molecular Mechanisms to Novel Treatments
Zuo, L., Prather, E. R., Stetskiv, M., Garrison, D. E., Meade, J. R., Peace, T. I., & Zhou, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184472 · Cited by 539
“Breast cancer remains the most common cancer in women, with more than 1 million new cases each year [118].”
BackgroundLangendijk, J. A., Lambin, P., De Ruysscher, D., Widder, J., Bos, M., & Verheij, M. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.05.007 · Cited by 549
“the development of cardiovascular complications after irradiation for breast cancer generally takes at least 5 years, and the incidence in particular continues to increase over twenty years after initial treatment [23–25].”
BackgroundStrongman, H., Gadd, S., Matthews, A., Mansfield, K. E., Stanway, S., Lyon, A. R., dos-Santos-Silva, I., Smeeth, L., & Bhaskaran, K. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31674-5 · Cited by 509
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Self-citationvan den Bogaard, V. A. B., Ta, B. D. P., van der Schaaf, A., Bouma, A. B., Middag, A. M. H., Bantema-Joppe, E. J., van Dijk, L. V., van Dijk-Peters, F. B. J., Marteijn, L. A. W., de Bock, G. H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.8480 · Cited by 511
“Both the end point and pretreatment risk factors were similar to those defined by Darby et al.6 Data Collection Patient characteristics, treatment plans, follow-up data, and information on cardiac risk factors and cardiac end points were retrospectively extracted from patient records of the Department of Radiation Onc…”
MethodResultInfluential2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.037 · Cited by 486
Charged-particle therapy in cancer: clinical uses and future perspectives
Durante, M., Orecchia, R., & Loeffler, J. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.30 · Cited by 484
Gilchrist, S. C., Barac, A., Ades, P. A., Alfano, C. M., Franklin, B. A., Jones, L. W., La Gerche, A., Ligibel, J. A., Lopez, G., Madan, K., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000679 · Cited by 472
Lancellotti, P., Nkomo, V. T., Badano, L. P., Bergler, J., Bogaert, J., Davin, L., Cosyns, B., Coucke, P., Dulgheru, R., Edvardsen, T., et al. (2013) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2013.07.005 · Cited by 484
Booth, C. M., & Tannock, I. F. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.725 · Cited by 469
“…disease and diabetes among men treated with androgen deprivation for localised prostate cancer (Keating et al, 2006), the risks of cardiac disease after radiotherapy for breast cancer (Darby et al, 2013), and long-term toxicities associated with treatment of testicular cancer (Fossa et al, 2007).”
Backgroundvan Nimwegen, F. A., Schaapveld, M., Cutter, D. J., Janus, C. P. M., Krol, A. D. G., Hauptmann, M., Kooijman, K., Roesink, J., van der Maazen, R., Darby, S. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4444 · Cited by 464
Self-citationCardiovascular Disease Mortality Among Breast Cancer Survivors
Bradshaw, P. T., Stevens, J., Khankari, N., Teitelbaum, S. L., Neugut, A. I., & Gammon, M. D. (2016) · Epidemiology · doi:10.1097/ede.0000000000000394 · Cited by 443
Evaluation and Management of Patients With Heart Disease and Cancer: Cardio-Oncology
Herrmann, J., Lerman, A., Sandhu, N. P., Villarraga, H. R., Mulvagh, S. L., & Kohli, M. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.05.013 · Cited by 422
Wang, K., Eblan, M. J., Deal, A. M., Lipner, M., Zagar, T. M., Wang, Y., Mavroidis, P., Lee, C. B., Jensen, B. C., Rosenman, J. G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.0229 · Cited by 428
“Third, assessing baseline cardiac risk via the WHO/ISH risk score and baseline CAD is imperfect, but it is still a reasonable and practical approach similar to those used by others.(3,8) Fourth, patients were treated over many years on multiple trials, which introduces treatment heterogeneity.”
BackgroundMethodThorsen, L. B. J., Offersen, B. V., Danø, H., Berg, M., Jensen, I., Pedersen, A. N., Zimmermann, S. J., Brodersen, H.-J., Overgaard, M., & Overgaard, J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.6456 · Cited by 426
“The rate of major coronary events, including ischemic heart death, has been found to be dependent on the mean heart dose.(23) The negative effect of cardiac irradiation may be aggravated by the addition of chemotherapy, which was used in greater than half of our patients.”
BackgroundBreast-Conserving Surgery with or without Irradiation in Early Breast Cancer
Kunkler, I. H., Williams, L. J., Jack, W. J. L., Cameron, D. A., & Dixon, J. M. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2207586 · Cited by 401
Role of microbiota-derived short-chain fatty acids in cancer development and prevention
Mirzaei, R., Afaghi, A., Babakhani, S., Sohrabi, M. R., Hosseini-Fard, S. R., Babolhavaeji, K., Khani Ali Akbari, S., Yousefimashouf, R., & Karampoor, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111619 · Cited by 394
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Benefits and harms of mammography screening
Løberg, M., Lousdal, M. L., Bretthauer, M., & Kalager, M. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0525-z · Cited by 368
“Risk of death from cardiovascular disease is increased in women treated with radiotherapy [38], and adjuvant treatment may be cardiotoxic (for example, taxanes, anthracyclines, or trastuzumab) [39].”
BackgroundČelutkienė, J., Pudil, R., López-Fernández, T., Grapsa, J., Nihoyannopoulos, P., Bergler-Klein, J., Cohen-Solal, A., Farmakis, D., Tocchetti, C. G., von Haehling, S., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1957 · Cited by 368
Patel, Z. S., Brunstetter, T. J., Tarver, W. J., Whitmire, A. M., Zwart, S. R., Smith, S. M., & Huff, J. L. (2020) · npj Microgravity · doi:10.1038/s41526-020-00124-6 · Cited by 373
Nuclear physics in particle therapy: a review
Durante, M., & Paganetti, H. (2016) · Reports on Progress in Physics · doi:10.1088/0034-4885/79/9/096702 · Cited by 345
Dess, R. T., Sun, Y., Matuszak, M. M., Sun, G., Soni, P. D., Bazzi, L., Murthy, V. L., Hearn, J. W. D., Kong, F.-M., Kalemkerian, G. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6142 · Cited by 362
Lancellotti, P., Nkomo, V. T., Badano, L. P., Bergler-Klein, J., Bogaert, J., Davin, L., Cosyns, B., Coucke, P., Dulgheru, R., Edvardsen, T., et al. (2013) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jet123 · Cited by 353
Radiation-Induced Endothelial Vascular Injury
Venkatesulu, B. P., Mahadevan, L. S., Aliru, M. L., Yang, X., Bodd, M. H., Singh, P. K., Yusuf, S. W., Abe, J.-I., & Krishnan, S. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.01.014 · Cited by 334
“Relative contributions of heart mitochondria glutathione peroxidase and catalase to HO(2) detoxification in in vivo conditions.”
BackgroundRecht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., Hudis, C. A., Hwang, E. S., Kirshner, J. J., Morrow, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.1188 · Cited by 340
Taylor, C. W., Wang, Z., Macaulay, E., Jagsi, R., Duane, F., & Darby, S. C. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.07.2292 · Cited by 332
Self-citationBloom, M. W., Hamo, C. E., Cardinale, D., Ky, B., Nohria, A., Baer, L., Skopicki, H., Lenihan, D. J., Gheorghiade, M., Lyon, A. R., et al. (2016) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002661 · Cited by 334
“Events occurred 5 years after initial exposure and continued through the third decade following exposure.(47)”
BackgroundAdjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality
Kerr, A. J., Dodwell, D., McGale, P., Holt, F., Duane, F., Mannu, G., Darby, S. C., & Taylor, C. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102375 · Cited by 307
“5) [18] (Table 3, Supplemental Table 8).”
Self-citationRadiation-Induced Heart Disease: Pathologic Abnormalities and Putative Mechanisms
Taunk, N. K., Haffty, B. G., Kostis, J. B., & Goyal, S. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00039 · Cited by 316
“However, new clinical data in breast cancer survivors suggest that there is no low-dose threshold that increases the risk of RIHD (6).”
BackgroundRadiation‐Induced Cardiovascular Disease: Review of an Underrecognized Pathology
Belzile‐Dugas, E., & Eisenberg, M. J. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021686 · Cited by 273
Kry, S. F., Bednarz, B., Howell, R. M., Dauer, L., Followill, D., Klein, E., Paganetti, H., Wang, B., Wuu, C., & George Xu, X. (2017) · Medical Physics · doi:10.1002/mp.12462 · Cited by 307
Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma
Cutter, D. J., Schaapveld, M., Darby, S. C., Hauptmann, M., van Nimwegen, F. A., Krol, A. D. G., Janus, C. P. M., van Leeuwen, F. E., & Aleman, B. M. P. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv008 · Cited by 310
“Recent studies in breast cancer patients have demonstrated a dose-response relationship for radiation-related ischaemic heart disease (11).”
BackgroundSelf-citationTime to abandon single-site irradiation for inducing abscopal effects
Brooks, E. D., & Chang, J. Y. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0119-7 · Cited by 313
Hersch, J., Barratt, A., Jansen, J., Irwig, L., McGeechan, K., Jacklyn, G., Thornton, H., Dhillon, H., Houssami, N., & McCaffery, K. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60123-4 · Cited by 289
A cardiac contouring atlas for radiotherapy
Duane, F., Aznar, M. C., Bartlett, F., Cutter, D. J., Darby, S. C., Jagsi, R., Lorenzen, E. L., McArdle, O., McGale, P., Myerson, S., et al. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.01.008 · Cited by 308
“…d, Ebbe L. Lorenzen e, Orla McArdle f, Paul McGale a, Saul Myerson g, Kazem Rahimi h, Sindu Vivekanandan i, Samantha Warren j, Carolyn W. Taylor a aClinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford; bMedical Research Council Population Health Research…”
BackgroundMethodInfluentialSelf-citationCardiovascular Complications of Cancer Therapy
Chang, H.-M., Okwuosa, T. M., Scarabelli, T., Moudgil, R., & Yeh, E. T. H. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1095 · Cited by 290
Vaidya, J. S., Bulsara, M., Baum, M., Wenz, F., Massarut, S., Pigorsch, S., Alvarado, M., Douek, M., Saunders, C., Flyger, H. L., et al. (2020) · BMJ · doi:10.1136/bmj.m2836 · Cited by 293
Speirs, C. K., DeWees, T. A., Rehman, S., Molotievschi, A., Velez, M. A., Mullen, D., Fergus, S., Trovo, M., Bradley, J. D., & Robinson, C. G. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.134 · Cited by 282
Radiation-induced heart disease: a review of classification, mechanism and prevention
Wang, H., Wei, J., Zheng, Q., Meng, L., Xin, Y., Yin, X., & Jiang, X. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.35460 · Cited by 269
“Clinical studies have demonstrated that the incidence of CAD in patients is up to 85%, it closely related to radiation dose, location, time, and other factors [3, 8].”
BackgroundCardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer
Atkins, K. M., Rawal, B., Chaunzwa, T. L., Lamba, N., Bitterman, D. S., Williams, C. L., Kozono, D. E., Baldini, E. H., Chen, A. B., Nguyen, P. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.500 · Cited by 274
Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions
Banfill, K., Giuliani, M., Aznar, M., Franks, K., McWilliam, A., Schmitt, M., Sun, F., Vozenin, M. C., & Faivre Finn, C. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.002 · Cited by 272
“In contrast to the QUANTEC recommendation suggesting that MHD less than 15 Gy is safe, Darby et al.31 reported for the first time that the risk of MACE (defined as MI, coronary revascularization, or death from IHD) in breast cancer survivors increases in a linear relationship to cardiac radiation dose, even at low-dos…”
BackgroundMethodMcSweeney, J. C., Rosenfeld, A. G., Abel, W. M., Braun, L. T., Burke, L. E., Daugherty, S. L., Fletcher, G. F., Gulati, M., Mehta, L. S., Pettey, C., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000381 · Cited by 263
“the absolute risk for IHD is highest in those women with preexisting CVD risk factors.(198) This increased risk for IHD may be”
BackgroundNuclear genomic instability and aging
Niedernhofer, L. J., Gurkar, A. U., Wang, Y., Vijg, J., Hoeijmakers, J. H. J., & Robbins, P. D. (2018) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-012239 · Cited by 275
Long‐Term Cardiovascular Risk After Radiotherapy in Women With Breast Cancer
Cheng, Y., Nie, X., Ji, C., Lin, X., Liu, L., Chen, X., Yao, H., & Wu, S. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005633 · Cited by 258
“A population-based case-control study by Darby et al suggested that exposure of the heart to ionizing radiation during breast cancer radiotherapy increased the subsequent rate of ischemic heart disease in a doseresponse relationship.(4) In contrast, a population-based cohort study by Boekel et al did not find an incre…”
BackgroundHeart in space: effect of the extraterrestrial environment on the cardiovascular system
Hughson, R. L., Helm, A., & Durante, M. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.157 · Cited by 257
Deep Inspiration Breath Hold—Based Radiation Therapy: A Clinical Review
Boda-Heggemann, J., Knopf, A.-C., Simeonova-Chergou, A., Wertz, H., Stieler, F., Jahnke, A., Jahnke, L., Fleckenstein, J., Vogel, L., Arns, A., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.11.049 · Cited by 247
How Safe Is Safe Enough? Radiation Risk for a Human Mission to Mars
Cucinotta, F. A., Kim, M.-H. Y., Chappell, L. J., & Huff, J. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074988 · Cited by 250
“However, the analysis made by current reports suggest that estimates of ERR do not vary significantly when adjustments for possible lifestyle factors are considered [8–10].”
BackgroundA systematic review of the cost and cost‐effectiveness studies of proton radiotherapy
Verma, V., Mishra, M. V., & Mehta, M. P. (2016) · Cancer · doi:10.1002/cncr.29882 · Cited by 242
Atkins, K. M., Chaunzwa, T. L., Lamba, N., Bitterman, D. S., Rawal, B., Bredfeldt, J., Williams, C. L., Kozono, D. E., Baldini, E. H., Nohria, A., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.6332 · Cited by 241
Screening Mammography in Older Women: A Review
Walter, L. C., & Schonberg, M. A. (2014) · JAMA · doi:10.1001/jama.2014.2834 · Cited by 241
Fatal heart disease among cancer patients
Stoltzfus, K. C., Zhang, Y., Sturgeon, K., Sinoway, L. I., Trifiletti, D. M., Chinchilli, V. M., & Zaorsky, N. G. (2020) · Nature Communications · doi:10.1038/s41467-020-15639-5 · Cited by 235
Saiki, H., Petersen, I. A., Scott, C. G., Bailey, K. R., Dunlay, S. M., Finley, R. R., Ruddy, K. J., Yan, E., & Redfield, M. M. (2017) · Circulation · doi:10.1161/circulationaha.116.025434 · Cited by 243
Heart toxicity from breast cancer radiotherapy: Current findings, assessment, and prevention
Piroth, M. D., Baumann, R., Budach, W., Dunst, J., Feyer, P., Fietkau, R., Haase, W., Harms, W., Hehr, T., Krug, D., et al. (2019) · Strahlentherapie und Onkologie · doi:10.1007/s00066-018-1378-z · Cited by 232
Bergom, C., Bradley, J. A., Ng, A. K., Samson, P., Robinson, C., Lopez-Mattei, J., & Mitchell, J. D. (2021) · JACC: CardioOncology · doi:10.1016/j.jaccao.2021.06.007 · Cited by 230
“MHD is the typical metric used to evaluate cardiac exposure in present-day clinical practice.”
BackgroundInfluentialCardiovascular Health of Patients With Cancer and Cancer Survivors
Barac, A., Murtagh, G., Carver, J. R., Chen, M. H., Freeman, A. M., Herrmann, J., Iliescu, C., Ky, B., Mayer, E. L., Okwuosa, T. M., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.04.059 · Cited by 229
Virani, S. A., Dent, S., Brezden-Masley, C., Clarke, B., Davis, M. K., Jassal, D. S., Johnson, C., Lemieux, J., Paterson, I., Sebag, I. A., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.02.078 · Cited by 231
“This increased risk was observed as early as 5 years after radiotherapy and continued for 3 decades.(60) The most important factors influencing RIHD are dose to the heart and the target volume.”
BackgroundGold nanoparticles in combinatorial cancer therapy strategies
Beik, J., Khateri, M., Khosravi, Z., Kamrava, S. K., Kooranifar, S., Ghaznavi, H., & Shakeri-Zadeh, A. (2019) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2019.02.025 · Cited by 229
Bergom, C., Currey, A., Desai, N., Tai, A., & Strauss, J. B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00087 · Cited by 215
“In fact, mean radiation dose to the heart correlates with rates of both cardiac deaths (7, 8) and coronary events (8, 9).”
BackgroundDelp, M. D., Charvat, J. M., Limoli, C. L., Globus, R. K., & Ghosh, P. (2016) · Scientific Reports · doi:10.1038/srep29901 · Cited by 216
Mulrooney, D. A., Armstrong, G. T., Huang, S., Ness, K. K., Ehrhardt, M. J., Joshi, V. M., Plana, J. C., Soliman, E. Z., Green, D. M., Srivastava, D., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-0424 · Cited by 220
“Coronary artery disease, typically associated with cardiac-directed radiation, has mostly been studied among survivors of Hodgkin lymphoma or breast cancer (32, 33).”
Campia, U., Moslehi, J. J., Amiri-Kordestani, L., Barac, A., Beckman, J. A., Chism, D. D., Cohen, P., Groarke, J. D., Herrmann, J., Reilly, C. M., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000641 · Cited by 217
Vascular toxic effects of cancer therapies
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0347-2 · Cited by 206
Cardiovascular Manifestations From Therapeutic Radiation
Mitchell, J. D., Cehic, D. A., Morgia, M., Bergom, C., Toohey, J., Guerrero, P. A., Ferencik, M., Kikuchi, R., Carver, J. R., Zaha, V. G., et al. (2021) · JACC: CardioOncology · doi:10.1016/j.jaccao.2021.06.003 · Cited by 208
“Baseline CV risk factors and CV disease have a substantial impact on the subsequent development of CV complications after RT (1-3).”
BackgroundInfluentialA review of clinical aspects of breast cancer
Libson, S., & Lippman, M. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2013.852971 · Cited by 211
Ionizing Radiation-Induced Endothelial Cell Senescence and Cardiovascular Diseases
Wang, Y., Boerma, M., & Zhou, D. (2016) · Radiation Research · doi:10.1667/rr14445.1 · Cited by 203
“Collectively, these findings suggest that the heart and vasculature might be more radiosensitive than was previously thought (10).”
BackgroundRisk of second primary lung cancer in women after radiotherapy for breast cancer
Grantzau, T., Thomsen, M. S., Væth, M., & Overgaard, J. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.05.004 · Cited by 204
“further estimated the dose–response correlation of radiation induced coronary events after radiotherapy for breast cancer among 2168 Swedish and Danish breast cancer patients, treated under DBCG guidelines (1958–2001) [40].”
Background
Metadata
- Authors
- Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., Jensen, M.-B., Nisbet, A., Peto, R., Rahimi, K., Taylor, C., & Hall, P.
- Affiliations
- University of Oxford (GB)
- University of Southern Denmark (DK)
- Karolinska Institutet (SE)
- Karolinska University Hospital (SE)
- Aalborg University Hospital (DK)
- University of South Florida (US)
- Danderyds sjukhus (SE)
- Rigshospitalet (DK)
- Royal Surrey County Hospital (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-03-14
- Volume
- 368
- Issue
- 11
- Pages
- 987-998
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2154375587
- Cited by
- 3,974
- References
- 38
- Citations by year
- 2026: 277 · 2025: 290 · 2024: 270 · 2023: 358 · 2022: 359 · 2021: 392 · 2020: 344 · 2019: 285 · 2018: 278 · 2017: 268 · 2016: 285 · 2015: 259 · 2014: 195 · 2013: 107
- FWCI
- 191.87
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Funders
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- Cancer Research UK
- National Institute for Health and Care Research (RRX 108)
- British Heart Foundation (RE/08/004, CRE RE/08/004)
- University of Oxford (RE/08/004)
- European Commission
- Medical Research Council
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Physical Sciences › Physics and Astronomy › Radiation › Advanced Radiotherapy Techniques
- Keywords
- breast cancer radiotherapy, ischemic heart disease, coronary events, myocardial infarction, coronary revascularization, radiation-induced heart disease, left anterior descending artery, radiation dose, cardiovascular risk factors, women
- MeSH terms
- Adult, Aged, Breast Neoplasms, Female, Heart, Humans, Mastectomy, Middle Aged, Radiation Injuries, Radiotherapy Dosage, Risk, Risk Factors, Case-Control Studies, Chemotherapy, Adjuvant, Myocardial Ischemia, Radiotherapy, Adjuvant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.